The clear, multi-dose solution is stable at ambient temperatures and intended for use as an ocular lubricant in conditions involving instability of the tear film leading to dry eye syndrome.
NovaTears®+Omega-3 lubricates and protects the corneal surface and thereby efficiently relieves the symptoms associated with dry eye like burning, itching, stinging and foreign body sensation. It further stabilizes the lipid layer of the tear film and reduces the evaporation of the underlying water phase of the tear film.
The product received its CE-marking in October 2017 and is commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears™ Omega by Ursapharm.
Safety, efficacy and comfort of Novatear®+Omega-3 is clinically validated in a multi-center, single-arm, post-market clinical follow-up study in patients with evaporative dry eye disea